Breaking News Instant updates and real-time market news.

SNAP

Snap

$17.36 /

+0.685 (+4.11%)

06:20
01/10/20
01/10
06:20
01/10/20
06:20

Snap initiated with an Outperform at Bernstein

Bernstein analyst Mark Shmulik initiated coverage of Snap with an Outperform rating and $20 price target as part of a broader initiation of the U.S. Internet sector with a generally positive outlook. Shmulik says that despite what outsiders may suggest, Snap's status as the social home for Gen Z and younger Millennials and undisputed innovator in social imaging and AR, is not at risk, adding that if anything, a renewed focus on this demographic, recent executive changes, continued ad product development, and clear ad buyer value proposition should contribute to a step change in ad share-of-wallet in 2020, though 4Q19 may come up short as ad buyers stretch out budgets.

  • 22

    Jan

  • 04

    Feb

SNAP Snap
$17.36 /

+0.685 (+4.11%)

01/09/20 COWN
Snap upgraded to Outperform at Cowen
01/09/20 JEFF
Jefferies sees 'room to run' for Snap, upgrades to Buy
01/09/20
Fly Intel: Top five analyst upgrades
01/09/20 BERN
Snap initiated with an Outperform at Bernstein

TODAY'S FREE FLY STORIES

Initiation
Mattel initiated with an Overweight at JPMorgan » 07:12
01/27/20
01/27
07:12
01/27/20
07:12
MAT

Mattel

$14.27 /

-0.17 (-1.18%)

JPMorgan analyst Tami…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Kennedy Wilson initiated with a Neutral at BofA » 07:12
01/27/20
01/27
07:12
01/27/20
07:12
KW

Kennedy Wilson

$22.16 /

-0.32 (-1.42%)

BofA analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Hasbro initiated with a Neutral at JPMorgan » 07:12
01/27/20
01/27
07:12
01/27/20
07:12
HAS

Hasbro

$104.71 /

-0.71 (-0.67%)

JPMorgan analyst Tami…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Anavex achieves enrollment target for ANAVEX 2-73 Phase 2 PDD trial » 07:12
01/27/20
01/27
07:12
01/27/20
07:12
AVXL

Anavex

$2.92 /

-0.08 (-2.67%)

Anavex Life Sciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Synchrony price target lowered to $37 from $43 at BMO Capital » 07:11
01/27/20
01/27
07:11
01/27/20
07:11
SYF

Synchrony

$32.63 /

-3.56 (-9.84%)

BMO Capital analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Rexnord sees annual increases in common dividend amount » 07:09
01/27/20
01/27
07:09
01/27/20
07:09
RXN

Rexnord

$32.26 /

-0.42 (-1.29%)

Rexnord announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
NuCana announces first patients dosed in Phase III study of Acelarin » 07:09
01/27/20
01/27
07:09
01/27/20
07:09
NCNA

NuCana

$5.11 /

-0.025 (-0.49%)

NuCana announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Rexnord expands share repurchase authorization to $300M » 07:08
01/27/20
01/27
07:08
01/27/20
07:08
RXN

Rexnord

$32.26 /

-0.42 (-1.29%)

The Rexnord board…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
EyePoint, Ocumension sign exclusive license agreement for DEXYCU » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
EYPT

EyePoint

$1.93 /

-0.06 (-3.02%)

EyePoint Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Kraft Heinz CEO wants to take fewer, but bigger bets on new products, WSJ says » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
KHC

Kraft Heinz

$30.41 /

-0.29 (-0.94%)

Kraft Heinz CEO Miguel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
JNJ

Johnson & Johnson

$148.32 /

-0.27 (-0.18%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca divests rights to established hypertension medicines » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

AstraZeneca announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Rexnord initiates quarterly dividend of 8c per share » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
RXN

Rexnord

$32.26 /

-0.42 (-1.29%)

The Rexnord board…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Aveo Pharmaceuticals, Biodesix present results from ficlatuzumab trial at ASCO » 07:06
01/27/20
01/27
07:06
01/27/20
07:06
AVEO

Aveo Pharmaceuticals

$0.59 /

-0.0188 (-3.08%)

Aveo Oncology and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Opus Bank reports Q4 adj. EPS 51c, consensus 37c » 07:05
01/27/20
01/27
07:05
01/27/20
07:05
OPB

Opus Bank

$24.80 /

-0.3 (-1.20%)

Reports Q4 book value per…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
NeuroMetrix reports Q4 revenue $1.7M, one estimate $4.28M » 07:05
01/27/20
01/27
07:05
01/27/20
07:05
NURO

NeuroMetrix

$4.71 /

+0.34 (+7.78%)

"Although we were…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
Recommendations
American Express price target raised to $120 from $115 at Credit Suisse » 07:04
01/27/20
01/27
07:04
01/27/20
07:04
AXP

American Express

$135.11 /

+3.71 (+2.82%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Oncolytics: Data identifies CEACAM6 as a prospective biomarker for pelareorep » 07:04
01/27/20
01/27
07:04
01/27/20
07:04
ONCY

Oncolytics

$3.25 /

-0.21 (-6.07%)

Oncolytics Biotech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Antares Pharma sees FY20 revenue $135M-$155M, consensus $149.16M » 07:04
01/27/20
01/27
07:04
01/27/20
07:04
ATRS

Antares Pharma

$3.99 /

-0.13 (-3.16%)

Robert Apple, president…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Evogene's subsidiary announces agreement with Hadasit medical center » 07:03
01/27/20
01/27
07:03
01/27/20
07:03
EVGN

Evogene

$1.69 /

+ (+0.00%)

Canonic, a wholly owned…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Upgrade
e.l.f. Beauty upgraded to Buy after 25% pullback at Jefferies » 07:03
01/27/20
01/27
07:03
01/27/20
07:03
ELF

e.l.f. Beauty

$14.93 /

-0.125 (-0.83%)

Jefferies analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Antares Pharma sees FY19 revenue 'at upper end' or exceeding $115M-$120M  07:03
01/27/20
01/27
07:03
01/27/20
07:03
ATRS

Antares Pharma

$3.99 /

-0.13 (-3.16%)

Consensus $118.26M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Sunniva to cease operations of Full-Scale Distributors by end of February » 07:02
01/27/20
01/27
07:02
01/27/20
07:02
SNNVF

Sunniva

$0.00 /

+ (+0.00%)

Sunniva announces that as…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Sorrento Therapeutics board rejects latest acquisition proposal » 07:01
01/27/20
01/27
07:01
01/27/20
07:01
SRNE

Sorrento Therapeutics

$4.29 /

+0.105 (+2.51%)

Sorrento Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Medpace downgraded to Hold from Buy at SunTrust » 07:01
01/27/20
01/27
07:01
01/27/20
07:01
MEDP

Medpace

$87.85 /

-3.37 (-3.69%)

SunTrust analyst Sandy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.